Point-of-care molecular diagnostics built on plasmonic biosensing, which detects nucleic acid targets without amplification. First test targets vaginitis with a result in about 15 minutes, with UTI and STI panels planned.
One email, every morning
THE MORNING BRIEF
New clearances, funding rounds and regulatory moves for device founders, and every new how-to guide and template as it lands. No noise, no login.
✓
You're in. The next morning brief lands in your inbox.
No Spam. Unsubscribe anytime.